ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

General Practice

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,312Medicare Part D Prescriptions Filled, Including Refills

Rank: 16 out of 45

$710K Total Retail Price of All Prescriptions

Rank: 15 out of 45

344 Patients Receiving at Least One Drug in Part D
67%Patients 65 Years and Older
47% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Kentucky
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

9% of this provider’s 344 patients filled at least one prescription for a schedule three drug, compared to an average of 25%.

Risky Drugs to Seniors

1% of this provider’s 6,586 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$69 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

30 is the average number of prescriptions (including refills) per patient, compared to an average of 25.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Kentucky
FENOFIBRATE 491 319 1 64
LEVOTHYROXINE SODIUM 374 270 2 5
PRAVASTATIN SODIUM 318 257 3 14
LISINOPRIL 314 170 4 2
OMEPRAZOLE 278 159 5 3
LISINOPRIL-HYDROCHLOROTHIAZIDE 264 171 6 29
RANITIDINE HCL 256 132 7 16
SIMVASTATIN 225 155 8 4
AMLODIPINE BESYLATE 215 187 9 7
ZETIA 182 107 10 50
GABAPENTIN 180 127 11 9
CITALOPRAM HBR 179 101 12 21
FUROSEMIDE 172 123 13 6
METFORMIN HCL 154 87 14 8
ZOLPIDEM TARTRATE 149 74 15 22
CARVEDILOL 144 81 16 25
ATORVASTATIN CALCIUM 144 84 16 12
METOPROLOL SUCCINATE 134 107 18 18
HYDROCHLOROTHIAZIDE 125 85 19 11
CYMBALTA 117 96 20 59
CRESTOR 117 50 20 23
ATENOLOL 113 81 22 15
METOPROLOL TARTRATE 102 64 23 10
LOVAZA 101 44 24 76
CLOPIDOGREL 101 79 24 26
NEXIUM 97 56 26 19
FLUTICASONE PROPIONATE 94 57 27 44
NIASPAN 94 65 27 118
TIZANIDINE HCL 90 27 29 41
TRAZODONE HCL 89 48 30 32
SPIRIVA 88 67 31 54
TRICOR 86 50 32 111
ALLOPURINOL 84 63 33 36
PLAVIX 84 67 33 35
SYNTHROID 83 68 35 125
WARFARIN SODIUM 82 68 36 17
GLIMEPIRIDE 74 44 37 72
PROAIR HFA 72 33 38 38
CLONIDINE HCL 70 21 39 61
TRAMADOL HCL 69 29 40 20
PANTOPRAZOLE SODIUM 65 38 41 31
LOSARTAN POTASSIUM 65 61 41 27
DEXILANT 63 41 43 235
SULFAMETHOXAZOLE-TRIMETHOPRIM 63 41 43 92
DIOVAN 60 41 45 43
DOXAZOSIN MESYLATE 56 35 46 67
MELOXICAM 55 38 47 28
PROMETHAZINE HCL 55 0 R 47 33
DILTIAZEM ER 54 41 49 116
SYMBICORT 54 38 49 129
LANTUS SOLOSTAR 53 17 51 149
DIOVAN HCT 51 34 52 122
BENICAR 50 50 53 257
PEN NEEDLE 50 28 53 161
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 1, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.